Stockscreener 앱 받기
30.95
0.13%
-0.04
전일 마감가:
$30.99
열려 있는:
$31.09
하루 거래량:
1.05M
Relative Volume:
0.55
시가총액:
$5.11B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
15.87
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
+3.17%
1개월 성능:
+3.37%
6개월 성능:
+4.95%
1년 성능:
+11.37%
1일 변동 폭
$30.70
$31.10
1주일 범위
$29.85
$31.68
52주 변동 폭
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
ALKS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
30.95 | 5.12B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
142.77 | 64.42B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.46 | 45.95B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
8.82 | 39.14B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.07 | 22.90B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
456.84 | 20.50B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Do Options Traders Know Something About Alkermes Stock We Don't? - Yahoo Finance
Robeco Institutional Asset Management B.V. Buys 36,467 Shares of Alkermes plc $ALKS - MarketBeat
Substance Abuse Treatment Market Size, Growth Analysis 2031 - openPR.com
Is Alkermes plc (8AK) stock at risk of policy regulationGold Moves & Daily Entry Point Alerts - newser.com
Is Alkermes plc reversing from oversold territoryTrade Risk Assessment & Reliable Breakout Stock Forecasts - newser.com
Is Alkermes plc (8AK) stock cheap vs fundamentalsWeekly Trading Summary & AI Optimized Trade Strategies - newser.com
Will Alkermes plc (8AK) stock hit Wall Street targetsVolume Spike & Comprehensive Market Scan Insights - newser.com
Technical analysis overview for Alkermes plc stockMarket Weekly Review & Fast Exit/Entry Strategy Plans - newser.com
Alkermes Plc Experiences Evaluation Revision Amidst Mixed Market Signals and Performance Trends - Markets Mojo
Alkermes sued over alleged scheme to block generic Vivitrol - Reuters
Is Alkermes plc a good long term investmentMACD Trading Signals & Investor Community Interactions - earlytimes.in
Will Alkermes plc (8AK) stock benefit from Fed rate cuts2025 Market Overview & Comprehensive Market Scan Insights - newser.com
Can Alkermes plc stock deliver strong Q4 earningsPortfolio Growth Summary & Fast Gaining Stock Reports - newser.com
How cyclical is Alkermes plc (8AK) stock compared to rivals2025 Trade Ideas & Free AI Powered Buy and Sell Recommendations - newser.com
What candlestick patterns are forming on Alkermes plcJuly 2025 Patterns & Fast Gain Stock Trading Tips - newser.com
Alkermes Plc Hits Day High with Strong 10.58% Intraday Surge - Markets Mojo
Alkermes (ALKS) Added to Wells Fargo's Tactical Ideas List - GuruFocus
What analysts say about Alkermes plc 8AK stockPrice-to-Earnings Ratio Insights & Budget Friendly Capital Growth - earlytimes.in
What drives Alkermes plc stock priceMarket Breadth Indicators & Explosive Profit Trading - earlytimes.in
Alkermes : Corporate Responsability Report - MarketScreener
Alkermes plc (ALKS) Stock Analysis: Exploring a 49.54% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
U.S. Buprenorphine Market Set for Dynamic Growth with Key - openPR.com
How Investors May Respond To Alkermes (ALKS) Phase 2 Alixorexton Narcolepsy Trial Outperformance - Sahm
Alkermes upgraded at RBC Capital Markets ahead of key catalyst - MSN
Is Alkermes' (ALKS) Narcolepsy Drug Breakthrough Shifting Its Investment Narrative? - Yahoo Finance
Alkermes Plc Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Alkermes' Stock Dip on Narcolepsy Data Seen as Buying Opportunity, RBC Says - MarketScreener
Alkermes stock upgraded at RBC Capital Markets (ALKS:NASDAQ) - Seeking Alpha
Alkermes (NASDAQ:ALKS) Shares Gap Up After Analyst Upgrade - MarketBeat
Alkermes (NASDAQ:ALKS) Upgraded by Royal Bank Of Canada to "Outperform" Rating - MarketBeat
RBC Capital Upgrades ALKS: Price Target Raised to $44 | ALKS Sto - GuruFocus
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.02%
0.10%
자본화:
|
볼륨(24시간):